These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17076593)

  • 1. The CNS as a target for peptides and peptide-based drugs.
    Banks WA
    Expert Opin Drug Deliv; 2006 Nov; 3(6):707-12. PubMed ID: 17076593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of peptides to the brain: emphasis on therapeutic development.
    Banks WA
    Biopolymers; 2008; 90(5):589-94. PubMed ID: 18335425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides.
    Qian S; Wang Q; Zuo Z
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1491-508. PubMed ID: 25196358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of therapeutic peptides and proteins to the CNS.
    Salameh TS; Banks WA
    Adv Pharmacol; 2014; 71():277-99. PubMed ID: 25307220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.
    Calias P; Banks WA; Begley D; Scarpa M; Dickson P
    Pharmacol Ther; 2014 Nov; 144(2):114-22. PubMed ID: 24854599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ; Thorne RG
    Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide prodrugs for the treatment of CNS disorders: a perspective for new drugs.
    Chin CM; Chiba DE; Machado MG; Vizioli Ede O; Santos JL
    Curr Med Chem; 2014; 21(23):2599-609. PubMed ID: 24533804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptides: important tools for the treatment of central nervous system disorders.
    Malavolta L; Cabral FR
    Neuropeptides; 2011 Oct; 45(5):309-16. PubMed ID: 21477861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide therapeutics for CNS indications.
    McGonigle P
    Biochem Pharmacol; 2012 Mar; 83(5):559-66. PubMed ID: 22051078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development.
    Wen MM
    Discov Med; 2011 Jun; 11(61):497-503. PubMed ID: 21712015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
    Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
    CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agile delivery of protein therapeutics to CNS.
    Yi X; Manickam DS; Brynskikh A; Kabanov AV
    J Control Release; 2014 Sep; 190():637-63. PubMed ID: 24956489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanotechnologies: a strategy to overcome blood-brain barrier.
    De Rosa G; Salzano G; Caraglia M; Abbruzzese A
    Curr Drug Metab; 2012 Jan; 13(1):61-9. PubMed ID: 22292810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases.
    Meredith ME; Salameh TS; Banks WA
    AAPS J; 2015 Jul; 17(4):780-7. PubMed ID: 25801717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics.
    Bourganis V; Kammona O; Alexopoulos A; Kiparissides C
    Eur J Pharm Biopharm; 2018 Jul; 128():337-362. PubMed ID: 29733950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors.
    Zhu J; Jiang Y; Xu G; Liu X
    Histol Histopathol; 2012 May; 27(5):537-48. PubMed ID: 22419018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Penetrating Peptides: As a Promising Theranostics Strategy to Circumvent the Blood-Brain Barrier for CNS Diseases.
    Varnamkhasti BS; Jafari S; Taghavi F; Alaei L; Izadi Z; Lotfabadi A; Dehghanian M; Jaymand M; Derakhshankhah H; Saboury AA
    Curr Drug Deliv; 2020; 17(5):375-386. PubMed ID: 32294035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.